Wealthcare Advisory Partners LLC acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 2,710 shares of the exchange traded fund’s stock, valued at approximately $257,000.
A number of other institutional investors have also recently bought and sold shares of the business. Concourse Financial Group Securities Inc. boosted its position in SPDR S&P Biotech ETF by 21.2% during the 4th quarter. Concourse Financial Group Securities Inc. now owns 658 shares of the exchange traded fund’s stock worth $59,000 after acquiring an additional 115 shares during the period. Verity Asset Management Inc. lifted its holdings in shares of SPDR S&P Biotech ETF by 0.8% during the 4th quarter. Verity Asset Management Inc. now owns 17,368 shares of the exchange traded fund’s stock valued at $1,551,000 after buying an additional 140 shares during the last quarter. Greenwich Wealth Management LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 1.4% during the 4th quarter. Greenwich Wealth Management LLC now owns 11,451 shares of the exchange traded fund’s stock valued at $1,022,000 after buying an additional 155 shares during the last quarter. Mesirow Institutional Investment Management Inc. lifted its holdings in shares of SPDR S&P Biotech ETF by 3.2% during the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 5,565 shares of the exchange traded fund’s stock valued at $497,000 after buying an additional 170 shares during the last quarter. Finally, HB Wealth Management LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 4.9% during the 4th quarter. HB Wealth Management LLC now owns 4,280 shares of the exchange traded fund’s stock valued at $382,000 after buying an additional 200 shares during the last quarter.
SPDR S&P Biotech ETF Price Performance
Shares of SPDR S&P Biotech ETF stock opened at $93.04 on Tuesday. The firm has a market cap of $7.09 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 52-week low of $63.80 and a 52-week high of $103.52. The stock has a 50-day simple moving average of $90.14 and a 200-day simple moving average of $90.90.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Insider Trades May Not Tell You What You Think
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Where Do I Find 52-Week Highs and Lows?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 3 Monster Growth Stocks to Buy Now
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.